Partner International is a global business development company focused on delivering outstanding results for clients worldwide in the life science sector.
Looking to advance your BD strategy? @PartnerIntl invites you to connect with our SVP, Mark Regular, at #BIOEurope in Cologne! Let's discuss your BD priorities and explore how we can help accelerate your objectives. Message us to arrange a meeting! #25years#Biotech#Pharma
@PartnerIntl is out-licensing three differentiated clinical and preclinical assets targeting Alzheimer’s Disease, dry age-related macular degeneration and dermatology. If you are seeking new programs in these areas, please reach out to learn more. #Pharma#Biotech#25years
@PartnerIntl is representing a client with a proprietary technology that enables precision particle engineering for small molecules and biologics, with potential to improve bioavailability, stability and drug delivery. Interested? DM us to learn more. #Pharma#Biotech#25years
@PartnerIntl is heading to BIOSpain in Bilbao!
We look forward to meeting with you to discuss how our global network, 25+ years of experience, and proven track record in licensing, partnering, and M&A can accelerate your BD objectives. Send a DM to set up a meeting! #25Years
@PartnerIntl is representing a leading AI-driven #biotech focused on accelerating the discovery of therapeutics and advanced materials through proprietary generative #AI platforms. If you are evaluating AI-platforms for drug discovery, we should connect. #drugdiscovery#25years
An outstanding week at #BIO2026, connecting with innovative biotech and pharma leaders to explore BD opportunities. It was a pleasure meeting so many familiar faces and making new contacts. If we didn't meet, let’s connect and discuss your BD priorities.
#Biotech#Pharma#25Years
@PartnerIntl is selling a clinical stage women’s health program in assistive reproduction. This is a great opportunity for companies focusing on OB/GYN and seeking innovative assets to add to the portfolio. Send a DM to get more info. #womenshealth#pharma#biotech#25years
@PartnerIntl is representing a leading EU CDMO offering full cGMP manufacturing of injectable drug products for clinical/commercial. If you need aseptic manufacturing of DNA vaccines, small molecules, proteins or peptides, send us a DM to learn more. #pharma#biotech#25years
Let’s meet at #BIO2026 in San Diego! Our Executive Team will be on-site and welcomes the chance to connect. We can explore how our global expertise and 25+ years of M&A/licensing experience can support your strategic objectives. Send us a DM to connect! #pharma#biotech#25years
Seeking a US Commercial Partner for a near approval CNS/ADHD product. If you have commercial infrastructure in the market and looking to add new, proprietary products to your portfolio, send @PartnerIntl a DM. #pharma#biotech#25years
@PartnerIntl has completed another transaction on behalf of one of our clients - a regional commercial deal for a late-stage CV asset. If you have BD objectives to partner your pipeline internationally, connect with us to see how we can be of support.
#Pharma#Biotech#25Years
Fantastic week at #BIOEuropeSpring in Lisbon, connecting with some of the most innovative teams in biotech and pharma and exploring new BD and partnership opportunities for 2026.
If we did not meet, let’s connect soon to discuss your BD priorities.
#pharma#biotech#25years
@PartnerIntl is seeking marketed products in specialist indications in the US/CAN for licensing/acquisition for an in-market client with strong commercial capabilities. If you have products available for a strategic transaction, please send us a DM. #pharma#biotech#25years
@PartnerIntl is representing a leading EU CDMO, focusing on next-generation RNA products, preclinical/clinical drug development, GMP-grade mRNA LNP/liposomal formulation, & sterile manufacturing. If you have a pipeline in this area, we should connect! #pharma#biotech#25years
@PartnerIntl invites you to meet our SVP Mark Regular #BIOEuropeSpring in Lisbon, to discuss how we can help you meet your BD objectives. We can explore how our relationships, 25+ years of experience, & track record can accelerate your transactions. Send a DM! #Biotech#25years
@PartnerIntl is partnering a CD22 targeted CAR-T therapy for B-Cell Malignancies. This novel CD22-CAR has activity as stand-alone and in a bi-specific setting. It is available as a fully-validated product, a CAR molecule, or a binder. DM to learn more. #pharma#biotech#25years
@PartnerIntl is pleased to welcome Dr. Jain Stephen to the team as a BD Associate.
Jain leverages a strong blend of scientific training and commercial acumen to support clients worldwide. She will work closely with our clients to execute their BD initiatives globally.